SANTA CLARA, Calif. & SAN CARLOS, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (NASDAQ:AFFX) and NuGEN Technologies Inc., a privately held company that develops and commercializes nucleic acid amplification and labeling systems for small and difficult samples, announced today their agreement to co-market a solution that enables researchers to access FFPE (formalin-fixed, paraffin-embedded) tissue samples derived from years of clinical studies previously inaccessible by traditional RNA amplification methods. The NuGEN WT-Ovation™ FFPE System provides scientists the opportunity to conduct global gene expression analysis on their vast archives of small and degraded FFPE samples, using standard Affymetrix GeneChip® 3’ expression arrays.
